US Patent 7713524 Use of ADCC-optimized antibodies for treating low-responder patients
All edits
Edits on 24 Apr, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 1 Feb, 2024
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Patent Citations Received
Edits on 31 Oct, 2023
Golden AI
Edits made to:
Article (+401 characters)
Article
Patent abstract
The invention concerns the use of human or humanized chimeric monoclonal antibodies which are produced in selected cell lines, said antibodies bringing about a high ADCC activity as well as a high secretion of cytokines and interleukins, for treating underpopulations of so-called weak-response patients exhibiting CD16 FCGR3A-158F homozygote or FCGR3A-158V/F heterozygote polymorphism.
Edits on 18 Sep, 2023
Golden AI
Edits made to:
Infobox (+7 properties)
Infobox
Patent Inventor Names
Christine Gaucher0
Christophe De Romeuf0
Dominique Bourel0
Emmanuel Nony0
Nicolas Bihoreau0
Philippe Klein0
Sylvie Jorieux0
Edits on 23 May, 2023
Golden AI
Edits made to:
Infobox (+1/-1 properties)
US Patent 07713524 Use of ADCC-optimized antibodies for treating low-responder patients US Patent 7713524 Use of ADCC-optimized antibodies for treating low-responder patients
Infobox
Patent Number
07713524
Patent Number
7713524
Golden AI
Edits made to:
Infobox (-1 properties)
Infobox
Official Website
Edits on 18 Jun, 2022
Golden AI
Edits made to:
Infobox (+1 properties)
Infobox
Website URL
Edits on 4 Dec, 2021
Golden AI
Edits made to:
Infobox (+7 properties)
US Patent 07713524 Use of ADCC-optimized antibodies for treating low-responder patients
Infobox
Is a
Patent jurisdiction
Patent number
07713524
Date of patent
May 11, 2010
Patent application number
10566358
Date Filed
July 30, 2004
Patent primary examiner
Find more entities like US Patent 7713524 Use of ADCC-optimized antibodies for treating low-responder patients
Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
